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The aim of these studies was to compare the efficacy and the safety of tiotropium,
delivered via Respimats Soft MistTM Inhaler (SMI), a novel multi-dose, propellant-free
inhaler, with ipratropium pressurized metered-dose inhaler (pMDI) in chronic obstructive
pulmonary disease (COPD) patients.
Two identical, 12-week, multi-national, randomized, double-blind, double-dummy,
parallel-group, active- and placebo-controlled studies were performed. COPD patients
were randomized to treatment with either inhaled tiotropium (5 or 10 mg) via Respimats
SMI administered once daily, ipratropium (36 mg) pMDI QID or placebo. The primary
endpoint was the mean trough forced expiratory volume in 1 s (FEV1) response after 12
weeks of treatment. Secondary endpoints included other spirometry measures and rescue
medication use.
A total of 719 patients were randomized; the majority were male (69%) with a mean pre-
bronchodilator FEV1 (% predicted) of 40.7%. The mean treatment differences between
tiotropium 5 and 10 mg and placebo for the primary endpoint (mean trough FEV1 response
at week 12) were 0.118 and 0.149 L, respectively (both Po0.0001). Treatment differences
between tiotropium 5 and 10 mg and ipratropium were 0.064 L (P ¼ 0.006) and 0.095 L
(Po0.0001). The increases in peak FEV1, FEV1 AUC(0–6 h) and FVC for both tiotropium doses
were statistically superior to placebo (Po0.01) and higher than ipratropium. All activeElsevier Ltd. All rights reserved.
778 7753; fax: +1 203 791 6158.
nger-ingelheim.com (E. Rubin).
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Tiotropium Respimats SMI in COPD 33treatments significantly reduced the rescue medication use compared with placebo, but
only tiotropium 10 mg was statistically superior to ipratropium (P ¼ 0.04). The incidence of
adverse events was comparable across groups.
In conclusion, tiotropium 5 and 10 mg daily, delivered via Respimats SMI, significantly
improved lung function compared with ipratropium pMDI and placebo.
& 2007 Elsevier Ltd. All rights reserved.Introduction
The anticholinergics, tiotropium and ipratropium, are
established options for first-line maintenance therapy for
the treatment of chronic obstructive pulmonary disease
(COPD).1–3 Ipratropium, however, has a short (i.e., p6-h)
duration of action, making repeated daily dosing necessary.
In contrast, tiotropium has a prolonged muscarinic M3
receptor blockade, leading to sustained 24-h efficacy with
once-daily dosing.3,4 Tiotropium has demonstrated super-
iority over salmeterol in several measures including forced
expiratory volume in 1 s (FEV1) after 6 months of treat-
ment.5,6 In addition, it has been shown to improve health
status and dyspnoea, and to reduce exacerbations and
hospitalizations compared with placebo and ipratropium.3,7
More recently, tiotropium has been demonstrated to
improve exercise endurance, and to decrease hyperinflation
in patients with COPD.8–10
In all these studies, tiotropium was administered via the
HandiHalers, which is a dry-powder, breath-actuated
inhaler.11 More recently, an alternative propellant-free,
multi-dose inhaler (Respimats Soft MistTM Inhaler [SMI]) has
been developed, which uses mechanical energy from a
spring, rather than inspiratory flow, to generate a fine, low-
velocity mist. Compared with pressurized metered-dose
inhalers (pMDIs), the fine particle fraction (o5.8 mm) from
Respimats SMI is approximately 2.5 times greater, the
velocity about five times slower, and the duration for dose
release is about seven times longer.12,13 These character-
istics increase lung-drug deposition, reduce oropharyngeal
deposition and simplify the co-ordination of actuation and
inhalation with Respimats SMI.14–17 The relative ease of use
of Respimats SMI, and patient preference over pMDIs and
dry-powder inhalers (DPIs), has been demonstrated in
several studies.18–20
The aim of the current studies was to compare the
efficacy and the safety of two doses of tiotropium delivered
once daily via Respimats SMI with placebo and ipratropium
pMDI administered four times daily in the treatment of
patients with COPD.Methods
Study design
Two identical, 12-week, randomized, double-blind, double-
dummy, placebo- and active-controlled, parallel-group
studies were conducted in 39 centres across Germany, Italy,
South Africa and Switzerland (#205.251) and in 25 centres
across the USA and Canada (#205.252). The studies were
designed to compare the efficacy and the safety of twoonce-daily inhaled doses of tiotropium (5 and 10 mg,
delivered via SPIRIVAs Respimats SMI) (Boehringer Ingel-
heim, Ingelheim am Rhein, Germany) with inhaled ipratro-
pium bromide (36 mg, delivered via pMDI) and placebo
(delivered via Respimats SMI and pMDI) in patients with
moderate-to-severe COPD. The double-dummy feature
prevented both investigators and patients from differentiat-
ing active drug from placebo, despite the different inhaler
devices, which could otherwise not be blinded. Both studies
included a 3-week follow-up period. The studies took place
from November 2002 to December 2003, and were con-
ducted according to the requirements of good clinical
practice and other international and local regulations. The
protocols were approved by independent ethics commit-
tees. The subjects were given comprehensive verbal and
written information about the objectives and possible risks
involved in participation in the study. All patients provided
written, informed consent to participate. The studies were
sponsored by Boehringer Ingelheim and Pfizer.
Participants
Males and females agedX40 years with a diagnosis of COPD,
moderate-to-severe airway obstruction with a pre-bronch-
odilator FEV1 of p60% of predicted normal, FEV1/forced
vital capacity (FVC) p70%,(based on ECCS values21) and a
smoking history of X10 pack-years were included. Patients
were excluded if they had a history of asthma, allergic
rhinitis, any other significant respiratory illness or if they
had a condition that could influence their ability to
participate in the study. Other exclusion criteria included
known hypersensitivity to anticholinergics, prior use of
tiotropium, regular use of daytime oxygen therapy, sig-
nificant alcohol or drug abuse or participation in another
study. Pregnant or nursing women, or women of child-
bearing potential not using contraception, were also
excluded.
Medication restrictions
Rescue medication (salbutamol pMDI) was permitted as
needed during the study. Oral corticosteroids (equivalent of
o10mg prednisone per day), orally inhaled corticosteroids,
theophyllines and mucolytics were allowed if stabilized for
at least 6 weeks prior to and throughout the study. Oral
b-adrenergics and other investigational drugs were not
allowed for at least 1 month prior to run-in. Cromolyn
sodium and nedocromil sodium were not allowed for at
least 3 months prior to run-in. Anticholinergics, inhaled
b-adrenergics other than salbutamol or fixed combination
inhalers were also not allowed during the treatment period.
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Following screening (Visit 1) and a 2-week run-in period,
eligible patients were randomized (Visit 2) to tiotropium,
ipratropium or placebo. Tiotropium was administered once
daily and ipratropium/placebo were delivered four times
daily. Tiotropium (5 mg [two actuations of 2.5 mg] or 10 mg
[two actuations of 5 mg]) was delivered via Respimats SMI
once daily in the morning with two inhalations of placebo
pMDI. A further two inhalations of placebo pMDI were taken
at midday, early evening and before bedtime to achieve
blinding. Ipratropium (36 mg [two actuations of 18 mg]) was
delivered via pMDI in the morning, together with two
inhalations of placebo Respimats SMI. A further two
inhalations of ipratropium pMDI were taken at midday, early
evening and before bedtime. For the placebo, two inhala-
tions of placebo Respimats SMI and two inhalations of
placebo pMDI were taken in the morning. A further two
inhalations of placebo pMDI were taken at midday, early
evening and before bedtime. Both the investigator and the
patient were blinded to the randomization process. All
medications were self-administered by the patient.
Assessments
The primary endpoint was the change in trough (i.e.,
morning pre-dose) FEV1 after 12 weeks of treatment.
Secondary spirometry endpoints included FVC, peak expira-
tory flow rate (PEFR) and the number of patients achieving
a 15% increase above baseline (i.e., pre-dose on test Day 1)
in FEV1. Spirometry measures were performed in accor
dance with American Thoracic Society criteria22 at 10
(75)min pre-dose and up to 6-h post-dose. PEFR was
recorded in patient diary cards. Other secondary endpoints
included the weekly mean number of occasions per day that
rescue medication (salbutamol) was used; the severity of
COPD symptoms (i.e., wheezing, shortness of breath,
coughing and tightness of chest), which was based on the
physician’s assessment of the patient’s condition during
the week prior to a clinic visit, and was rated from 0
(not present) to 3 (severe); the physician’s global evalua-
tion of the patient’s condition, which was rated on an 8-
point scale from poor (1–2) to excellent (7–8). Safety was
assessed by adverse events, vital signs, 12-lead electro-
cardiograms (ECG), routine laboratory tests and physical
examination.
Statistical analysis
The protocol stated that the statistical analyses were to be
performed both for the individual studies and on the
combined data from the two studies. Efficacy was to be
established in each study. This paper describes the
combined analysis. The primary analysis was a step-wise
procedure that sequentially tested each tiotropium dose,
first for superiority vs. placebo, then for non-inferiority vs.
ipratropium and (assuming the initial tests were successful)
for superiority vs. ipratropium (a total of six hypothesis
tests). An analysis of covariance (ANCOVA), which used
terms for smoking status, treatment and centre, and
baseline as a linear covariate, was performed for theprimary endpoint, secondary spirometry endpoints, physi-
cian’s global evaluation and COPD symptom scores. Separate
ANCOVA models were fitted for each timepoint and test day.
Descriptive statistics were used for safety variables. Adverse
events were coded using the Medical Dictionary for
Regulatory Activities (MedDRA) version 8.0 and classified
by system organ class and preferred terms. All randomized
patients with any available data were included in the safety
evaluation, and all those with baseline data and at least one
adequate measurement of trough lung function parameters
following X5 days of randomized treatment were included
in the efficacy analysis (full analysis set).
Results
Patient characteristics
A total of 361 and 358 patients were randomized to
treatment in trials #205.251 and #205.252, respectively.
The patient characteristics at baseline are shown in Table 1.
Patients were comparable across treatment groups; overall,
69% were male, with a mean age of 64 years (standard
deviation [SD] 9) and 97% were white. The mean duration of
COPD was 10 years (SD 8) and the mean smoking history was
51 pack-years (SD 29). The pooled mean FEV1, FVC and PEFR
were similar across treatment groups, and a significant
proportion of patients (46%) were global initiative for
chronic obstructive lung disease (GOLD) stage II (i.e., 50%
ppost-bronchodilator FEV1o80%). Mean baseline rescue
salbutamol use, which was assessed during the run-in
period, was also comparable between-treatment groups. A
total of 87 patients (12%) discontinued prematurely (16 in
the tiotropium 5 mg group, 18 in the tiotropium 10 mg group,
31 in the ipratropium group and 22 on placebo).
Primary endpoint
Compared with placebo, there was an increase in trough
FEV1 after treatment with tiotropium 5 and 10 mg (Table 2).
‘‘Steady state’’ was achieved in the first week of therapy for
the tiotropium 5 mg dose, and the improvement in both the
tiotropium groups was sustained after 12 weeks of treat-
ment. The increase in trough FEV1 at week 12 in both the
tiotropium groups was statistically superior to that observed
with placebo (both Po0.0001), and was statistically super-
ior compared with ipratropium 36 mg (Po0.01). The im-
provement in FEV1 after 1 week was sustained at 12 weeks of
treatment.
Secondary endpoints
The pooled mean FEV1 response, measured pre-dose
(trough) up to 6-h post-dose is shown in Figure 1 for test
Days 1 and 85. The secondary spirometry endpoints are
summarized in Table 3. The increases in peak FEV1, FEV1
AUC(0–6 h), trough FVC, peak FVC and FVC AUC(0–6 h) at week
12 for both tiotropium doses (5 and 10 mg) were all
statistically superior to placebo, and both the doses of
tiotropium were numerically higher than ipratropium
for these measures; this difference reached statistical
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Table 1 Patients demographics and pulmonary function test results by treatment group for all randomized patients at
screening.
Variablesy Tiotropium 5 mg
Respimats (n ¼ 180)
Tiotropium 10 mg
Respimats (n ¼ 180)
Ipratropium
36mg pMDI
(n ¼ 178)
Placebo
(n ¼ 181)
Male (%) 69 72 67 69
Age (years) 64 (9) 64 (9) 65 (8) 63 (9)
Current smoker (%) 37 37 40 43
Smoking history (pack-
years)
52 (30) 53 (31) 48 (25) 51 (30)
Duration of COPD (years) 10 (8) 10 (9) 10 (7) 9 (7)
FEV1 (L) 1.10 (0.42) 1.14 (0.41) 1.16 (0.43) 1.20 (0.40)
FVC (L) 2.40 (0.83) 2.46 (0.81) 2.43 (0.83) 2.53 (0.81)
FEV1 (% predicted) 40 (12) 39 (12) 41 (13) 42 (12)
FEV1/FVC (%) 47 (11) 47 (11) 48 (11) 48 (11)
PEFR (morning) (L/min)z 221 (78) 238 (87) 236 (90) 241 (82)
Rescue salbutamol use
(occasions per day)z
2.9 (2.5) 3.0 (2.7) 2.9 (2.6) 2.4 (2.4)
GOLD stage (%)y
X80% o1 0 0 o 1
50–o80% 41 42 49 52
30–o50% 47 44 39 37
o30% 12 13 11 10
Patients (%) taking pulmonary medication (425%)
Inhaled corticosteroids 48 51 50 52
b-Agonists, long acting 39 44 43 40
b-Agonists, short acting 69 67 69 64
Anticholinergics, short
acting
48 46 47 45
pMDI, pressurized metered-dose inhaler; FEV1, forced expiratory volume in 1 s; FVC, forced vital capacity; PEFR, peak expiratory flow
rate; GOLD, global initiative for chronic obstructive lung disease.
Patients were comparable across treatment groups.
yMean (SD) unless otherwise stated.
zn ¼ 683.
yPost-bronchodilator FEV1 expressed as % of predicted.
Table 2 Treatment differences for mean trough FEV1 (L) response at week 12 (n ¼ 689).
Treatment
difference
Treatment comparisons
Tiotropium
5 mg–placebo
Tiotropium
10mg–placebo
Tiotropium
5 mg–ipratropium
36 mg
Tiotropium
10mg–ipratropium
36mg
Mean (SE) 0.118** (0.023) 0.149** (0.023) 0.064* (0.023) 0.095** (0.023)
[95% CI] [0.072, 0.164] [0.103, 0.195] [0.018, 0.110] [0.050, 0.141]
FEV1, forced expiratory volume in 1 s; SE, standard error; CI, confidence interval.*Po0.01; **Po0.0001.
Tiotropium Respimats SMI in COPD 35significance for FVC AUC(0–6 h) and trough FVC (tiotropium
10 mg dose only). These findings support those observed for
the primary variable. The weekly morning (trough) and
evening PEFR were both higher for the tiotropium groups
than either placebo or ipratropium over the 12-week
treatment period (Figure 2). The between-treatment
differences at week 12 were statistically significant, show-ing that both the doses of tiotropium were superior to
placebo and ipratropium (largest: Po0.001) (Table 3).
The number of responders (X15% increase in FEV1 above
test Day 1 pre-dose) within 2 h of dosing is shown in Figure 3.
A higher proportion of patients in the ipratropium group
achieved a 15% increase during test Day 1 compared with
either tiotropium or placebo; however, after 12 weeks of
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Figure 1 The mean FEV1 (L) response up to 6-h post-dose following treatment with tiotropium 5 mg Respimat
s SMI (n ¼ 175),
tiotropium 10mg Respimats SMI (n ¼ 173), ipratropium 36mg pMDI (n ¼ 170) or placebo (n ¼ 171). Data are expressed as change from
baseline on Day 1 (a) and after 12 weeks of treatment (b). FEV1, forced expiratory volume in 1 s; ***Po0.0001 tiotropium–placebo.
Note: Missing data were imputed by carrying either the lowest or last value forward depending on why the data were missing. Means
were adjusted for smoking status, investigational centre and baseline FEV1 using ANCOVA. A separate ANCOVA was fitted for each
time point and test day.
T. Voshaar et al.36treatment the number of responders in the three active
treatments was comparable: tiotropium 5 mg (70%), tiotro-
pium 10 mg (72%), ipratropium 36 mg (69%).
All three active treatments reduced the rescue medication
use throughout the 12-week study period compared with
placebo (Figure 4). The between-treatment differences showed
statistical superiority over placebo for tiotropium 5mg (P ¼
0.0061) and tiotropium 10mg (Po0.0001), but only tiotropium
10mg was statistically superior to ipratropium (P ¼ 0.04).
At week 12, the scores for the COPD symptoms ‘‘wheez-
ing’’ and ‘‘tightness of chest’’ were statistically significantly
lower for tiotropium 5 mg (Po0.05 vs. placebo) and
tiotropium 10 mg (Po0.05 vs. placebo), and the ‘‘tightness
of chest’’ score was significantly lower for tiotropium 5 mg
than ipratropium (P ¼ 0.0021) and for tiotropium 10 mg thanipratropium (P ¼ 0.0141). There were little differences
between active treatments for ‘‘shortness of breath’’ or
‘‘coughing’’ after 12 weeks of treatment. Both the tiotro-
pium doses significantly improved physician’s global evalua-
tion score on each test day compared with placebo
(Pp0.02); however, ipratropium showed minor improve-
ments compared with placebo. During the 3-week follow-up
period, there was no evidence of a rebound effect following
the cessation of treatment. At 3-week post-treatment, the
mean number of occasions of rescue medication use was
0.5 to 0.6 per 24 h on active treatment and 0.2 per 24 h
on placebo, and, at 3-week post-treatment, the morning
PEFR (L/min) was also higher on Respimats SMI 5 and 10 mg
(23 and 20 L/min) compared with ipratropium (11 L/min)
and placebo (13 L/min).
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Table 3 Treatment differences for pooled secondary spirometry endpoints at week 12 (n ¼ 689).
Treatment difference,
mean (SE)
Treatment comparisons
Tiotropium
5mg–placebo
Tiotropium
10 mg–placebo
Tiotropium
5 mg–ipratropium 36mg
Tiotropium
10 mg–ipratropium 36mg
FEV1 AUC(0–6 h) 0.191*** (0.025) 0.214*** (0.025) 0.025 (0.025) 0.048 (0.025)
[95% CI] [0.142, 0.241] [0.164, 0.264] [0.024, 0.075] [0.001, 0.098]
FEV1 peak(0–6 h) 0.193*** (0.028) 0.229*** (0.028) 0.012 (0.028) 0.048 (0.028)
[95% CI] [0.138, 0.248] [0.173, 0.284] [0.042, 0.067] [0.007, 0.103]
Trough FVC (L) 0.132* (0.046) 0.180*** (0.046) 0.077 (0.046) 0.125* (0.046)
[95% CI] [0.041, 0.223] [0.089, 0.271] [0.014, 0.168] [0.036, 0.216]
Morning PEFR (L/min) 25*** (5) 23*** (5) 24*** (5) 21*** (5)
[95% CI] [15, 36] [12, 33] [13, 34] [11, 32]
Evening PEFR (L/min) 32*** (6) 29*** (6) 22*** (6) 19** (6)
[95% CI] [21, 43] [18, 40] [11, 33] [8, 30]
SE, standard error; FEV1, forced expiratory volume in 1 s; AUC, area under the curve; CI, confidence interval; FVC, forced vital
capacity; PEFR, peak expiratory flow rate.*Po0.01; **Po0.001; ***Po0.0001.
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The total incidence of adverse events was comparable
across treatment groups (Table 4). ‘‘Respiratory, thoracic
and mediastinal disorders’’ were the most frequently
reported MedDRA system organ class of adverse events
across all groups. Gastrointestinal disorders were more
common in the active treatment than placebo groups. Both
the tiotropium groups were associated with a higher
incidence of dry mouth than ipratropium or placebo:
tiotropium 5 mg (8.9%), tiotropium 10 mg (10%), ipratropium
(4.5%) and placebo (2.2%). There were no withdrawals due
to dry mouth. The percentage of patients who discontinued
due to an adverse event was lower in the tiotropium groups
than in the ipratropium group: tiotropium 5 mg (7.2%),
tiotropium 10 mg (6.7%), ipratropium (11.8%) and placebo
(8.8%). Unexpected worsening of COPD was the most
common reason for discontinuation: tiotropium 5 mg
(3.3%), tiotropium 10 mg (1.7%), ipratropium (6.2%) and
placebo (6.1%). The number of patients who experienced
serious adverse events was low: tiotropium 5 mg (0.6%),
tiotropium 10 mg (1.4%), ipratropium (2.4%) and placebo
(0.7%). Two deaths occurred in the tiotropium 10 mg group,
which were due to exacerbation of COPD with respiratory
failure and cardiac arrest, and one pancreatic cancer-
related death occurred in the ipratropium group. There
were no clinically relevant changes in the vital signs, the
physical examinations and 12-lead ECG throughout the
studies.Discussion
The aim of this active- and placebo-controlled combined
analysis was to determine the efficacy and the safety of
tiotropium, delivered via Respimats SMI, compared with
ipratropium administered using a pMDI. The pooled analysis
showed that once-daily tiotropium (5 and 10 mg) significantly
increased 12-week trough FEV1, the primary endpoint,
compared with ipratropium pMDI administered four timesdaily and placebo. Trough FEV1 is an important measure,
since it represents the minimum improvement experienced
by the patient during the course of the dosing period and,
for tiotropium, indicates the effects a full day after the
preceding dose. Overall, the number of clinically relevant
therapeutic responders after 12 weeks of treatment was
comparable with all active treatments. These findings show
that full efficacy (i.e., ‘‘steady-state’’) improvements with
tiotropium, delivered via Respimats SMI, were achieved in
the first week of the treatment, and were sustained after 12
weeks of the treatment, with no evidence of the develop-
ment of tolerance.
Both tiotropium 5 and 10 mg also improved the secondary
spirometry measures, compared with both placebo and
ipratropium. The sustained improvement in FVC observed
with tiotropium has important potential benefits as it is
frequently associated with reductions in hyperinflation and
symptoms associated with the latter.3,7,9,23 In addition,
significant improvements in COPD symptom scores for
wheezing and tightness of chest were observed for both
the doses of tiotropium, compared with placebo. Tiotropium
also reduced the need for rescue medication compared with
placebo and ipratropium. This may be related to the
sustained improvement in lung function seen with tiotro-
pium compared with ipratropium. Despite its more rapid
onset of action, ipratropium has a considerably shorter
duration of effect, as seen in the 6-h post-dose profiles of
FEV1 performed at weeks 1 and 12. This would also explain
the lower morning (trough) PEFR values compared with both
the doses of tiotropium.
The results observed in this study, in which tiotropium was
delivered via Respimats SMI, are generally comparable to
previous studies using the HandiHalers.24 In a 1-year trial
with the latter, the mean increase in trough and peak FEV1
relative to placebo was 150 and 220mL, respectively,7 and,
in two trials, improvements compared with placebo and
ipratropium on outcomes such as exacerbations, hospitali-
zations and heath-related quality of life over a 12-month
treatment period were statistically superior.3,7 Given that
the spirometric and other results obtained with tiotropium
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Figure 2 The weekly mean change in PEFR (L/min) following treatment with tiotropium 5 mg Respimats SMI (n ¼ 174), tiotropium
10mg Respimats SMI (n ¼ 170), ipratropium 36 mg pMDI (n ¼ 167–168) or placebo (n ¼ 169). Morning PEFR data are shown in (a) and
evening PEFR data are shown in (b). PEFR, peak expiratory flow rate; ***Po0.0001 tiotropium–placebo. Note: Missing data were
imputed by carrying either the lowest or last value forward depending on why the data were missing. Means were adjusted for
smoking status, investigational centre and baseline morning PEFR using ANCOVA. A separate ANCOVA was fitted for each week.
T. Voshaar et al.38in the current trial were similar to those seen with the
HandiHalers, similar effects on other health-related out-
comes may be anticipated, but must be examined in further
studies.
Although tiotropium is well established as COPD main-
tenance therapy when used with the HandiHalers device,
these results support its use with a new device, Respimats
SMI. Two randomized studies that compared tiotropium
delivery via HandiHalers or Respimats SMI in COPD patients
have been completed.25 A pooled analysis showed that after
4 weeks of treatment, the mean trough FEV1 was statisti-
cally significantly higher (30mL) following treatment with
tiotropium 5 and 10 mg Respimats SMI compared with
tiotropium 18 mg HandiHalers. The current analysis shows
that Respimats SMI significantly improved lung function
when compared with another first-line therapy, ipratropium
pMDI. Overall, these analyses clearly demonstrate the
benefits associated with the Respimats SMI device. How-ever, the current study does have a number of limitations. It
is well established that tiotropium can improve inspirational
capacity and reduce the operational lung volumes of COPD
patients, which correlates with an improvement in dyspnoea
and quality of life; however, such measurements were
outside the scope of the present studies.
Recent reports suggest that the response to treatment in
COPD can be hindered by inhaler technique, and patient
satisfaction and adherence.26 Metered-dose inhalers (MDIs)
and DPIs have a number of problems; for example, patients
can find it difficult to co-ordinate actuation with inhalation
with pMDI devices. Small volume nebulizers (SVNs) are
easier to use, but the size of the equipment can be a
limitation.27 Design convergence has enabled the beneficial
features of an SVN and an MDI to be combined, which has
resulted in the development of Respimats SMI.27
Drug delivery via Respimats SMI is independent of
inspiratory effort and the device is easily portable.
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Figure 3 The percentage of responders (defined as aX15% increase in FEV1 above baseline from 2 h of dosing) following treatment
with tiotropium 5 mg Respimats SMI (n ¼ 175), tiotropium 10 mg Respimats SMI (n ¼ 173), ipratropium 36mg pMDI (n ¼ 170) or
placebo (n ¼ 171). Data are shown on Day 1 and after 12 weeks of treatment. FEV1, forced expiratory volume in 1 s.
Figure 4 The mean weekly reduction in the rescue medication use following 12 weeks of treatment with tiotropium 5 mg Respimats
SMI (n ¼ 174), tiotropium 10mg Respimats SMI (n ¼ 171), ipratropium 36 mg pMDI (n ¼ 168) or placebo (n ¼ 170). *Po0.01;
**Po0.001; ***Po0.0001—placebo. Note: Missing data were imputed by carrying either the lowest or last value forward depending
on why the data were missing. Means were adjusted for smoking status, investigational centre and baseline rescue use using ANCOVA.
A separate ANCOVA was fitted for each week.
Table 4 Number (%) of patients with adverse events (X3%) in any treatment group.
Total, n (%) Tiotropium 5mg Respimats
(n ¼ 180)
Tiotropium 10mg Respimats
(n ¼ 180)
Ipratropium 36 mg
(n ¼ 178)
Placebo
(n ¼ 181)
Total with any adverse
event
95 (52.8) 108 (60.0) 106 (59.6) 107 (59.1)
Diarrhoea 3 (1.7) 4 (2.2) 6 (3.4) 4 (2.2)
Dry mouth 15 (8.3) 18 (10) 7 (3.9) 4 (2.2)
Nausea 0 (0) 3 (1.7) 6 (3.4) 3 (1.7)
Urinary tract infection 9 (5.0) 4 (2.2) 3 (1.7) 4 (2.2)
Headache 6 (3.3) 8 (4.4) 7 (3.9) 13 (7.2)
Bronchitis 8 (4.4) 3 (1.7) 8 (4.5) 7 (3.9)
COPD exacerbations 17 (9.4) 26 (14.4) 24 (13.5) 21 (11.6)
Dyspnoea 4 (2.2) 5 (2.8) 9 (5.1) 9 (5.0)
Pharyngitis 7 (3.9) 8 (4.4) 8 (4.5) 12 (6.6)
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T. Voshaar et al.40Respimats SMI offers another form of delivery of tiotro-
pium, thus offering the prescribers and the patients a
choice. In addition, a patient who has used tiotropium
HandiHalers for a long time may be able to switch to
tiotropium Respimats SMI if needed. Switching could also
improve (or alter) deposition, and enable a drug to be used
longer without dosing or tolerance issues, although these
benefits have not been proven in clinical trials. Further-
more, Respimats SMI improves the delivery of drug to
the lungs.12–17 In addition, this delivery device allows for
a lower inhaled dose with a comparable efficacy to the
HandiHalers.25
In published systematic reviews of the DPIs, the MDIs and
the nebulizers for delivering inhaled drugs, the devices were
found to be equally efficacious (if used correctly) and one of
the driving factors for successful therapy was patient
preference and adherence.28 Although Respimats SMI was
not included in these meta-analyses, a recently published
randomized controlled trial, in which Berodual Respimats
SMI was compared with Berodual MDI in 245 patients, 81%
(162/201) preferred Respimats SMI.19 Overall, these dis-
cussions suggest that Respimats SMI could be a valuable
addition for use in the COPD maintenance therapy. In the
current analysis, the results clearly showed that Respimats
SMI was particularly beneficial in patients with moderate-to-
severe airway obstruction. Other studies are underway to
explore the benefits of Respimats SMI in a wider patient
population.
The safety profile of tiotropium has been well estab-
lished. As in the previous clinical studies, dry mouth,
attributable to the anticholinergic effect of tiotropium,
was the most commonly reported adverse event in the
current study, and occurred more frequently than in
patients treated with ipratropium and placebo.3,6,7,23 The
similar efficacy and safety results in the current study
achieved at a lower dose of tiotropium in the Respimats SMI
compared with the HandiHalers are consistent with the
previous studies confirming superior drug delivery to the
lower respiratory tract achieved with the Respimats SMI.
In conclusion, tiotropium (5 and 10 mg), when delivered
via Respimats SMI, is safe and significantly improves
objective lung function compared with placebo and ipra-
tropium, delivered via a pMDI. Respimats SMI also provides
symptomatic benefits.Acknowledgements
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